Gilead Sciences, Inc. (NASDAQ:GILD) BofA Securities 2024 Health Care Conference May 14, 2024 2:20 PM ET Company Participants Geoff Meacham - Bank of America Securities Conference Call Participants Andrew Dickinson - Chief Financial Officer Geoff Meacham For the first day of the BofA Healthcare Conference. My name is Geoff Meacham. I'm the senior biopharma analyst here. We're thrilled today to have Gilead Sciences. And with me on stage is CFO, Andy Dickinson. Andy, good to see you. Andrew Dickinson Thank yo ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission File No. 0-19731 GILEAD SCIENCES, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 94-3047598 (State or Other Jurisdi ...

Gilead Sciences, Inc. (GILD) reported better-than-expected results in the first quarter, as its loss was narrower than expected and sales beat estimates.GILD’s first-quarter adjusted loss per share of $1.32 per share was narrower than the Zacks Consensus Estimate of a loss of $1.49. In the year-ago quarter, the company reported adjusted earnings of $1.37 per share.The year-over-year decrease was due to an acquired in-process research and development (IPR&D) charge of $3.9 billion, or $3.14 per share, relate ...

Gilead Sciences, Inc. (NASDAQ:GILD) Q1 2024 Earnings Conference Call April 25, 2024 4:30 PM ET Company Participants Jacquie Ross - Vice President, Investor Relations Daniel O'Day - Chairman and Chief Executive Officer Johanna Mercier - Chief Commercial Officer Merdad Parsey - Chief Medical Officer Andrew Dickinson - Chief Financial Officer Cindy Perettie - Executive Vice President, Kite Conference Call Participants Chris Schott - JPMorgan Daina Graybosch - Leerink Partners Umer Raffat - Evercore ISI Tyler V ...

Q124 Financial Results A p r i l 2 5 , 2 0 2 4 Forward-Looking Statements Statements included in this presentation that are not historical in nature are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Gilead cautions readers that forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include those relating to: Gilead’s ability to achieve its anticipate ...

For the quarter ended March 2024, Gilead Sciences (GILD) reported revenue of $6.69 billion, up 5.3% over the same period last year. EPS came in at -$1.32, compared to $1.37 in the year-ago quarter.The reported revenue represents a surprise of +5.59% over the Zacks Consensus Estimate of $6.33 billion. With the consensus EPS estimate being -$1.49, the EPS surprise was +11.41%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street ...

Gilead Sciences (GILD) came out with a quarterly loss of $1.32 per share versus the Zacks Consensus Estimate of a loss of $1.49. This compares to earnings of $1.37 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 11.41%. A quarter ago, it was expected that this HIV and hepatitis C drugmaker would post earnings of $1.76 per share when it actually produced earnings of $1.72, delivering a surprise of -2.27%.Over the last four quar ...

GILEAD SCIENCES ANNOUNCES FIRST QUARTER 2024 FINANCIAL RESULTS Product Sales Excluding Veklury Increased 6% Year-Over-Year to $6.1 billion Biktarvy Sales Increased 10% Year-Over-Year to $2.9 billion Oncology Sales Increased 18% Year-Over-Year to $789 million Closed CymaBay Acquisition Resulting in $3.9 billion Acquired IPR&D Charge ($3.14 Diluted EPS Impact) Foster City, CA, April 25, 2024 - Gilead Sciences, Inc. (Nasdaq: GILD) announced today its first quarter 2024 results of operations. “Gilead delivered ...

Gilead Sciences Inc. (GILD) is set to report first-quarter 2024 results on Apr 25, after market close. In the last reported quarter, the company posted an earnings surprise of -2.27%.Factors to NoteGilead has a market-leading HIV franchise, led by flagship HIV therapies — Biktarvy and Descovy. However, revenues in the first quarter might have been impacted by a decline in HIV franchise sales. The first quarter is typically impacted by the reset of patient copays and deductibles. In addition, inventory build ...

In the latest trading session, Gilead Sciences (GILD) closed at $66.16, marking a -1.15% move from the previous day. The stock fell short of the S&P 500, which registered a loss of 0.22% for the day. Elsewhere, the Dow gained 0.06%, while the tech-heavy Nasdaq lost 0.52%.The HIV and hepatitis C drugmaker's stock has dropped by 9.53% in the past month, falling short of the Medical sector's loss of 6.22% and the S&P 500's loss of 1.66%.The investment community will be closely monitoring the performance of Gil ...